PerkinElmer Strikes Deal With BioImage; Leverages Existing Strengths to Tackle HCS | GenomeWeb

As the high-content cell-based screening market heats up, another publicly traded company has joined the fray.

Instrument giant PerkinElmer announced recently that it will collaborate with Danish biotechnology firm BioImage to develop cell-based assays on the PerkinElmer EnVision HTS plate reader. BioImage said that it has already developed a suite of assays called GRIP for measuring protein-protein interactions in living cells, and that those assays have been validated on the EnVision. Financial terms of the agreement were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.